Introduction {#Sec1}
============

Traumatic brain injury (TBI) is a major cause of disability and death in adolescence. It has been suggested that mitigating brain damage and promoting nerve functional recovery following TBI would alleviate the burden to patients and to society \[[@CR1]\]. TBI-induced secondary injury is a complicated pathophysiological process that includes microglial activation, inflammatory responses, oxidative stress, and abnormal mitochondrial activities, all of which affect neurological function \[[@CR2]--[@CR4]\]. Damaged mitochondria release excess reactive oxygen species (ROS) after TBI, which lead to lipid peroxidation and cytotoxicity resulting in further oxidative stress and mitochondrial dysfunction \[[@CR5]--[@CR7]\]. Mitochondrial dysfunction in turn damages membrane permeability, causing excess release of mitochondrial apoptosis-associated proteins, which all promote caspase-dependent neuronal apoptosis \[[@CR8]\]. This process involves the upregulation of caspase-3, the pro-apoptotic factor B cell lymphoma (Bcl)-2-associated X protein (Bax), and the inhibition of the anti-apoptotic protein, Bcl-2 \[[@CR5]\].

The relationship between autophagy and apoptosis in the neurologic system is very complex and not fully understood. Considerable evidence suggests that autophagy can inhibit apoptosis based on diverse mechanisms, including that increasing autophagy removes damaged mitochondria or inactivation proteins \[[@CR5], [@CR9], [@CR10]\]. As reviewed by Fernandez, sequestering of unfolded protein which are initiators of endoplasmic reticulum stress by autophagy can also reduce apoptosis \[[@CR11]\]. Oxidative stress-induced autophagy selectively degrades oxidized substances and damages organelles to reduce oxidative injury, maintains normal mitochondrial function, and balances the intracellular microenvironment \[[@CR10], [@CR12], [@CR13]\]. Other factors involved in autophagy may be due to the molecular interactions between autophagy and apoptotic processes. Enhancing autophagy after TBI may decrease the expressions of neuronal apoptosis-related downstream molecules, including cleaved caspase-3, Bcl-2, and Bax, resulting in the dissociation of the Bcl-2/Beclin-1 complexes \[[@CR14]--[@CR16]\]. Our previous study \[[@CR17]\] also showed that the upregulation of autophagy could attenuate TBI-induced oxidative stress and apoptosis, suggesting a protective role of autophagy after TBI. Therefore, identifying neuroprotective mechanisms that are involved in autophagy-mediated neuronal apoptosis may provide novel therapeutic strategies for TBI.

Autophagy-related genes (ATGs) perform important roles in autophagy, which control major steps in the autophagic pathway, such as growth of autophagic membranes, recognition of autophagic cargoes, and fusion of autophagosomes with lysosomes \[[@CR18]--[@CR20]\]. Beclin-1, also known as BECN1, is the homolog of the mammalian yeast protein, ATG6. As an important factor in autophagy regulation, Beclin-1 can induce the formation of pre-autophagosomal structures to promote the generation of autophagic vacuoles \[[@CR21]--[@CR23]\]. Beclin-1 interacts with several binding partners and exerts multiple-biological effects, including cell metabolism, apoptosis, and autophagy \[[@CR16]\]. The suppression of Beclin-1 impairs the autophagy-associated post-translational processing of ATG8 ([microtubule-associated protein 1 light chain 3](http://www.so.com/link?m=a%2FedqJcuwH6evI%2FeCslYM1z144IXtBonaPr3CI10e78z89i6VvOhYLAu4xjSj3KIPEAQQF%2Bhw7dAEUSZF9V4nGl%2FQ1dkgErZR72rN4Gsbwcb9LWsfqlFlN48%2FUXPVLhpvttuU1aU2uC8yZ0VWtD0HtysNBxQLODIE), LC3) \[[@CR24]\]. Interaction with phosphatidylinositide 3-kinase (PI3K) can lead to upregulation of autophagy, while interactions with Bcl-2 can result in inhibition of apoptosis \[[@CR18]\].

Recent research has demonstrated that the deacetylation of ATGs by the sirtuin (SIRT) family of proteins is necessary for the induction of autophagosome formation \[[@CR25]--[@CR27]\]. SIRT1 is an nicotinamide adenine dinucleotide (NAD+)-dependent class III histone deacetylase and has been shown to regulate autophagy through the deacetylation of ATGs, which in turn plays major roles in regulating metabolism, DNA damage repair, and stress resistance \[[@CR24], [@CR26]\]. Furthermore, Beclin-1 expression levels are related acetylation of its lysine residues \[[@CR26], [@CR29]\]. Acetylation of Beclin-1 can lead to inhibition of autophagic responses, while deacetylation of Beclin-1 at lysine residues 430 and 437 by SIRT1 influences autophagosome maturation and subsequent biological effects \[[@CR29]\]. These findings suggest that Beclin-1 may be a novel deacetylation target of SIRT1, which in turn elevates the autophagy pathway through Beclin-1 deacetylation \[[@CR28]\].

Omega-3 polyunsaturated fatty acids (ω-3 PUFA), including eicosapentaenoic acid and docosahexaenoic acid, are known to be biologically active compounds with antioxidative and anti-inflammatory effects; all of which influence the pathogenesis of many diseases, including Alzheimer's disease \[[@CR29]\], acute pancreatitis \[[@CR30]\], Parkinson's disease \[[@CR31]\], and cerebral ischemia \[[@CR32]\]. We previously reported that ω-3 PUFA supplementation inhibited the neuroinflammatory response and neuronal apoptosis by regulating the HMGB1/NF-κB signaling pathway \[[@CR33]\]. In addition, SIRT1 levels were upregulated after ω-3 PUFA supplementation \[[@CR33], [@CR34]\]. We also demonstrated that ω-3 PUFA supplementation attenuates neuronal apoptosis by modulating the neuroinflammatory response through SIRT1-mediated deacetylation of the HMGB1/NF-κB pathway, leading to neuroprotective effects following experimental TBI \[[@CR33]\]. Other research has also demonstrated that ω-3 PUFA supplementation regulates oxidative stress and inflammation by the autophagy pathway \[[@CR34]--[@CR36]\]; although the mechanism of ω-3 PUFA-mediated autophagy pathway regulation still needs further clarification. The interaction between apoptosis and autophagy provides novel therapeutic strategies for TBI \[[@CR10], [@CR37]\]. Post-translational modifications like lysine deacetylations and deacetylation of Beclin-1 by SIRT1 influence autophagy and autophagy-mediated neuronal survival \[[@CR26], [@CR28]\], which raises the possibility that neuronal apoptosis may be attenuated by modulating SIRT1-mediated deacetylation of Beclin-1 after ω-3 PUFA supplementation. Thus, in the present study, the neuroprotective effects of ω-3 PUFAs against TBI-induced neuronal apoptosis were studied. In addition, the potential molecular mechanisms focusing on the autophagy pathway and SIRT1-mediated Beclin-1 deacetylation were also investigated.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

All animal experiments were approved by the Fujian Provincial Medical University Experimental Animal Ethics Committee (Fuzhou, China) and were performed under strict supervision. Adult male Sprague-Dawley rats, ranging between 230 and 260 g, were purchased from the Experimental Animal Facility in Fujian Medical University and housed in a temperature (23 ± 2 °C) and light (12 h light/dark cycle) controlled room with ad libitum access to food and water.

Experimental model and drug administration {#Sec4}
------------------------------------------

All rats were randomly assigned into a sham group, a sham+ω-3 PUFA supplementation group (sham+ω-3 group), a TBI group, and a TBI+ω-3 group. After injury, the groups were further divided into four subgroups: a 1-day group, a 3-day group, a 7-day group, and a 14-day group (*n* = 12 each). Six rats in each group were sacrificed for neurological evaluation and histological studies; the remaining six rats were used for molecular studies. TBI was induced in anesthetized (50 mg/kg sodium pentobarbital; intraperitoneally) rats as described previously \[[@CR33]\]. Briefly, a midline incision was made over the skull, and a 5-mm craniotomy was drilled through the skull 2 mm caudal to the left coronal suture and 2 mm from the midline without disturbing the dura. TBI was induced using a weight-drop hitting device (ZH-ZYQ, Electronic Technology Development Co., Xuzhou, China) with a 4.5-mm-diameter cylinder bar weighing 40 g from a height of 20 cm. Bone wax was used to seal the hole, and the scalp was sutured. All procedures were the same for each group except in the sham group, in which no weight was dropped. Approximately 30 min after TBI, the TBI+ω-3 group was intraperitoneally injected with ω-3 PUFA (2 ml/kg, diluted in dimethyl sulfoxide; Sigma, St. Louis, MO, USA) once per day for 7 consecutive days \[[@CR33]\]. To inhibit autophagy or the SIRT1 pathway, 25 ul/kg 3-methyladenine (3-MA, 1 mmol/l, diluted in dimethyl sulfoxide; Sigma) or 25 ul/kg sirtinol (2 mmol/l, diluted in dimethyl sulfoxide; Sigma) was administered into the right lateral ventricle 24 h after intraperitoneal ω-3 PUFA injection once per day for 3 consecutive days, in order to clarify the mechanisms of ω-3 PUFA-mediated neuroprotection \[[@CR38]\]. The remaining groups were injected with the same dose of dimethyl sulfoxide as a control.

Measurement of neurological impairment scores and the rotarod test {#Sec5}
------------------------------------------------------------------

Neurological deficit was calculated using the neurological impairment score. Rats were subjected to exercise (muscular state and abnormal action), sensation (visual, tactile, and balance), and reflex examinations and assigned a modified neurological severity score (mNSS) \[[@CR33]\] that was recorded when a task failed to be completed or when the corresponding reflex was lost. The mNSS score was graded on a scale of 0--18, where a total score of 18 points indicated severe neurological deficits and a score of 0 indicated normal performance, 13--18 points indicated severe injury, 7--12 indicated mean-moderate injury, and 1--6 indicated mild injury. Neurological function was measured at different time points by investigators who were blinded to group information.

The rotarod protocol was modified slightly from that in a previous report \[[@CR39]\]. Briefly, rats underwent a 2-day testing phase with a rotarod (IITC Life Science, Woodland Hills, CA, USA), which gradually accelerated from 5 to 45 rpm over 5 min. During the procedure, the latency to fall was recorded as the time before rats fell off or gripped the rod for two successive revolutions from day 1 after TBI. The mean latency was measured at different time points by investigators who were blinded to the experimental groups.

Measurement of brain water content {#Sec6}
----------------------------------

Brain water content was calculated using the wet weight-dry weight method \[[@CR33]\]. Animals were sacrificed after the mNSS test, and their cortices were removed at the edge of the bone window (200 ± 20 mg). Filter paper was used to remove excess blood and cerebrospinal fluid. The wet weight was measured, and the brains were dried in an oven at 100 °C for 24 h until a constant weight was achieved, at which point the dry weight was measured. The % brain water content was calculated as: (wet weight − dry weight)/wet weight × 100%.

Nissl staining {#Sec7}
--------------

Formaldehyde-fixed specimens were embedded in paraffin and cut into 4-μm-thick sections that were deparaffinized with xylene and rehydrated in a graded series of alcohol. Samples were treated with Nissl staining solution for 5 min. Damaged neurons were shrunken or contained vacuoles, whereas normal neurons had a relatively large, full soma, and round, large nuclei. Average intensities or cell counts were calculated from the same sections in six rats per group with Image-Pro Plus 7.0 by investigators who were blinded to the experimental groups.

Immunohistochemical analysis {#Sec8}
----------------------------

Formaldehyde-fixed specimens were embedded in paraffin and cut into 4-μm-thick sections that were deparaffinized with xylene and rehydrated in a graded series of alcohol. Antigen retrieval was carried out by microwaving in citric acid buffer. Sections were incubated with an antibody against SIRT1 (1:100; Cell Signaling Technology, Danvers, MA, USA), washed, and then incubated with secondary antibody for 1 h at room temperature. The negative control was prepared without the addition of the anti-SIRT1 antibody. A total of five sections from each animal were used for quantification, and the signal intensity was evaluated as follows \[[@CR36]\]: 0, no positive cells; 1, very few positive cells; 2, moderate number of positive cells; 3, large number of positive cells; and 4, the highest number of positive cells.

Immunofluorescence analysis {#Sec9}
---------------------------

Formaldehyde-fixed specimens were embedded in paraffin and cut into 4-μm-thick sections that were deparaffinized with xylene and rehydrated in a graded series of alcohol, followed by antigen retrieval. Sections were incubated overnight at 4 °C with antibodies against LC3 (1:200, Abcam, Cambridge, UK), NeuN (1:100; Boster Biotech, Wuhan, China), and Beclin-1 (1:200; Cell Signaling Technology). After washing, the sections were incubated with secondary antibodies for 1 h at room temperature. Cell nuclei were stained with 4′,6-diamidino-2-phenylindole. Immunopositive cells in five selected fields were counted under a microscope (Leica, Wetzlar, Germany) at × 400 magnification by investigators who were blinded to the experimental groups.

Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay {#Sec10}
--------------------------------------------------------------------------

Apoptotic cells were detected using a TUNEL kit (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. Indicators of apoptosis included a shrunken cell body, irregular shape, nuclear condensation, and brown diaminobenzidine staining, as observed by microscopy at × 400 magnification. The final average percentage of TUNEL-positive cells of the six sections was regarded as the data for each sample.

Primary culture of rat hippocampal neurons {#Sec11}
------------------------------------------

Rat brain tissues were homogenized and digested in preheated 0.25% trypsin-EDTA solution. The cells were resuspensed in Dulbecco's modified Eagle's medium (DMEM, low glucose) and cultured in DMEM medium (high glucose) supplemented with 10% FBS in 6-well cell culture plates at 37 °C in a 5% CO~2~ atmosphere.

SIRT1 siRNA transfection and autophagy flux analysis {#Sec12}
----------------------------------------------------

After 3 days, hippocampal neuron cells were transiently transfected with either siRNA control or the SIRT1 siRNA set in confocal petri dishes, using Lipo 2000 (Invitrogen, USA) according to the manufacturer's instructions. Both specific and control siRNAs were purchased from KeyGEN Biotech (Nanjing, China). Within 48 h, the cells were treated with mRFP-GFP-LC3 adenovirus with polybrene at a MOI = 30 and incubated for 36 h. The adenovirus was obtained from Hannbio (Shanghai, China). The cells were treated with 50 uM ω-3 PUFA and then washed with two time with 10 mM PBS, pH 7.4. Finally, cells were fixed with 4% paraformaldehyde at room temperature for 30 min and sealed with 50% glycerin/PBS. LC3 expression detection was carried on a confocal microscope (PerkinElmer, UltraView ERS). The mRFP-GFP-LC3 puncta number in the sample groups was quantified usingImage Pro Plus 6.0. and GraphPad 7.0.

Nuclear and cytoplasmic protein extraction {#Sec13}
------------------------------------------

The tissue samples were subjected to subcellular fractionation using the cytoplasmic and nuclear protein extraction kit (KGP150, KeyGEN Biotech, Nanjing, China), using hypotonic lysis buffer (20 mM HEPES (pH 7.4), 2 mM EGTA, 2 mM MgCl2) to extract the cytosolic protein and hypertonic lysis buffer (20 mM Tris/HCl, pH 7.6, 100 mM NaCl, 20 mM KCl, 1.5 mM MgCl 2, 0.5% Nonidet P-40, and protease inhibitors) to extract the nuclear protein. The protein concentration of the lysates was determined separately via western blot by stripping the polyvinylidene difluoride (PVDF) membranes and re-probing them with laminB1 (Cell Signaling Technology) as the nuclear control and β-actin (Boster Biotech) as the cytosolic control.

Western blotting {#Sec14}
----------------

Proteins were extracted with radioimmunoprecipitation assay lysis buffer (sc-24948; Santa Cruz Biotechnology). Proteins (30 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane that was probed with primary antibodies against B cell lymphoma (Bcl)-2 (1:400), Bax (1:200), LC3-1(1:400) and P62 (1:400), (all from Abcam); HO-1 (1:200), NQO1 (1:200), and UGT1A1 (1:200) (all from Santa Cruz Biotechnology Inc); and cleaved caspase-3 (1:200), Beclin-1 (1:200), ATG-3 (1:400), and ATG-7 (1:400; all from Cell Signaling Technology), followed by incubation with appropriate secondary antibodies. Immunoreactivity was visualized with the ECL Western Blotting Detection System (Millipore, Billerica, MA, USA). Gray value analysis was conducted with the UN-Scan-It 6.1 software (Silk Scientific Inc., Orem, UT, USA). Expression levels were normalized against β-actin (1:5000, Boster Biotech) or laminin B1 (1:3000, Cell Signaling Technology).

Immunoprecipitation (IP) {#Sec15}
------------------------

Lesioned cortices were processed with IP lysis Buffer (KGP701, KeyGEN Biotech), and subsequent homogenates were incubated with 1 μg of Beclin-1 antibody (Cell Signaling Technology) overnight at 4 °C. A 10-μl volume of protein A agarose beads (Roche, Mannheim, Germany) was added to the sample lysate for 2 h incubation at 4 °C. After IP and centrifugation, agarose beads were washed three times with lysis buffer and the homogenate were separated by SDS-PAGE and transferred to a PVDF membrane to detectBeclin-1 expression. PVDF membranes were then stripped and reprobed with an acetyl-lysine antibody. Total acetylation levels were measured with a pan-acetyl-lysine site-specific antibody, which was purchased from Immunechem (ICP0380, KeyGEN Biotech).

Activity assay {#Sec16}
--------------

The 2′,7′-dichlorodihydrofluorescein diacetate assay was applied to detect ROS concentrations in lesioned cortices according to the manufacturer's instructions (Yeasen Biotech Co., Ltd., Nanjing, China). Fluorescence signals were detected using a fluorescence microplate system (Enspire 2300, PerkinElmer, Norwalk, CT, USA) with a wavelength of 498 nm. The NAD+/NADH ratio was measured using the NAD+/NADH QuantificationColorimetricKit (Yusen Biotech, Shanghai, China) according to the manufacturer's instructions. The absorbance at 450 nm of the mixture was measured by a microplate reader (2030 ARVO).

Statistical analysis {#Sec17}
--------------------

All statistical analyses were performed using SPSS 18.0 statistical software (SPSS Inc., Chicago, IL, USA). The results were expressed as mean ± standard deviation. Statistical differences among the groups were assessed by one-way ANOVA and post hoc multiple comparisons were performed using Student-Newman-Keuls tests. Values of *p* \< 0.05 were considered statistically significant.

Results {#Sec18}
=======

Neuroprotective effects of ω-3 PUFA supplementation on TBI {#Sec19}
----------------------------------------------------------

The neurological function scores of the sham and sham+ω-3 PUFA groups were unaltered at all time points (scored 1--3). However, neurological function was severely impaired 1 day after TBI (12.59 ± 0.78); from day 3 after TBI, rats in the TBI+ω-3 PUFA group showed significantly better neurological functions than rats in the TBI group (10.31 ± 0.43 vs 12.03 ± 0.53, *p* \< 0.05) (Fig. [1](#Fig1){ref-type="fig"}c). In addition, rats in the TBI+ω-3 PUFA group showed significantly improved rotarod performances than rats in the TBI group from day 7 after TBI (72.01 ± 8.21 vs 53.11 ± 7.13, *p* \< 0.05) (Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1ω-3 PUFA supplementation improves neurological function and reduces brain edema after TBI. **a** Experimental scheme of ω-3 PUFA supplementation after TBI. **b** A schematic of a brain section after TBI. Areas in red refer to lesioned sites and areas in blue refer to sample points. **c** ω-3 PUFA supplementation improved neurological functions 3 days after TBI (10.31 ± 0.43 vs 12.03 ± 0.53, *p* \< 0.05). **d** Rats in the TBI+ω-3 PUFA group showed significantly improved rotarod performances than rats in the TBI groups from day 7 after TBI (72.01 ± 8.21 vs 53.11 ± 7.13, *p* \< 0.05). **e** ω-3 PUFA supplementation decreased brain water content 3 days after TBI (80.26% ± 0.61% vs 81.92% ± 0.72%, *p* \< 0.05). Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01

Brain water content is an important predictor of TBI prognosis \[[@CR33]\]. Compared with the sham group, the water content of brain tissue was higher (81.92% ± 0.72%) in the TBI group 3 days after injury (*p* \< 0.05). The water content of the TBI+ω-3 PUFA group was markedly lower than that of the TBI group (80.26% ± 0.61% vs 81.92% ± 0.72%, *p* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}e).

ω-3 PUFA supplementation protects neurons against TBI-induced neuronal apoptosis {#Sec20}
--------------------------------------------------------------------------------

Nissl staining was used to identify apoptotic neurons in lesioned cortices \[[@CR33]\]. The sham group and the sham+ω-3 PUFA group showed a very low apoptotic fraction of neurons. The percentage of apoptotic cells was higher in the TBI group than in the sham group 7 days after TBI (*p* \< 0.05); while the apoptotic fraction was significantly lower in the TBI+ω-3 PUFA than in the TBI group (39.19 ± 4.72% vs 73.42 ± 9.36%, *p* \< 0.05; Fig. [2](#Fig2){ref-type="fig"}a, b). Western blot analyses revealed that TBI resulted in the upregulation of apoptotic factors in the cortex 7 days after TBI; however, compared to the TBI group, cleaved caspase-3 and Bax levels were decreased, whereas the anti-apoptotic factor, Bcl-2, was increased in the TBI+ω-3 PUFA group (*p* \< 0.05: Fig. [2](#Fig2){ref-type="fig"}c). TUNEL staining further demonstrated that TUNEL-positive neurons were significantly decreased in the TBI+ω-3 group 7 days after TBI compared with the TBI group (47.72% ± 6.90% vs 81.41% ± 9.78%, *p* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}d). These results suggest that ω-3 PUFA supplementation inhibits neuronal apoptosis and exerts a neuroprotective effect after TBI.Fig. 2ω-3 PUFA supplementation protects neurons against TBI-induced neuronal apoptosis in the lesioned cortex 7 day after TBI. **a**, **b** The sham group and the sham+ω-3 PUFA group had very low fractions of apoptotic neurons. The percentage of apoptotic cells was higher in the TBI group than in the sham group (*p* \< 0.05); the apoptotic fraction was significantly lower in the TBI+ω-3 PUFA group than in the TBI group (39.19% ± 4.72% vs 73.42% ± 9.36%, *p* \< 0.05). Representative photomicrographs of Nissl-stained neurons are shown; arrows indicate apoptotic neurons. **c** Western blot analyses revealed that TBI resulted in the upregulation of apoptotic factors in the cortex; however, compared with the TBI group, cleaved caspase-3 and Bax levels were decreased, whereas the anti-apoptotic factor, Bcl-2, was increased in TBI+ω-3 PUFA group (*p* \< 0.05). **d** TUNEL staining demonstrated that TUNEL-positive neurons were significantly decreased in the TBI+ω-3 group compared with the TBI group (47.72% ± 6.90% vs 81.41% ± 9.78%, *p* \< 0.05). Representative photomicrographs of TUNEL-positive neurons are shown (× 400); arrows indicate apoptotic neurons. Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01. Scale bars = 50 μm

ω-3 PUFA supplementation protects neurons via enhancement of autophagy {#Sec21}
----------------------------------------------------------------------

Numerous studies have shown that enhancing autophagy may decrease the expression of neuronal apoptosis-related downstream molecules, thereby exerting neuroprotection after TBI \[[@CR40]\]. Therefore, changes in autophagy activity after TBI were measured in each of the groups. Immunofluorescence staining and western blot analysis showed that compared with the TBI group, expression levels of autophagic markers (LC3-II, Beclin-1, ATG-3, and ATG-7) were dramatically increased in the TBI+ω-3 PUFA group 7 day after TBI (*p* \< 0.05; Fig. [3](#Fig3){ref-type="fig"}a, b). The ω-3 PUFA group showed a suppression of autophagy at late stages compared with the early stage suppression of the control group, while SIRT1 siRNA or autophagy inhibitor reversed ω-3 PUFA-mediated increases in autophagy (*p* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}a, b). Western blot showed a significant increase in LC3 expression and a decrease in p62 levels in the ω-3 PUFA treatment group, which suggested a fluent autophagy degradation was mediated by the fusion of autophagosomes and lysosomes. However, the SIRT1 siRNA or autophagy inhibitor group showed an increase in p62 levels but no significant increases in LC3 expression (*p* \< 0.05; Fig. [4](#Fig4){ref-type="fig"}c).Fig. 3(**a**,**b**) Immunofluorescence staining showed that LC-positive neurons significantly increased following ω-3 PUFA supplementation. While, the autophagic inhibitor, 3-MA, attenuated LC-positive neuron expressions. Representative photomicrographs of LC-positive neurons are shown (× 400). (**c**,**d**) Western blot analysis showed that expression levels of autophagic markers (LC3-II, Beclin-1, ATG-3, and ATG-7) were dramatically increased in the TBI+ω-3 PUFA group 7 day after TBI (*p* \< 0.05), while 3-MA inhibited ω-3 PUFA-induced autophagy responses. Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01. Scale bars = 50 μmFig. 4ω-3 PUFA supplementation promotes autophagic flux on rat hippocampal neurons in vitro. **a** Autophagy markers LC3 with GFP and RFP protein which indicate real-time autophagy flux levels were imaged by confocal microscope (× 400). Representative photomicrographs of autophagy flux in neurons are shown. **b** Bar graphs displayed the mean ± standard deviation of the LC3 puncta per cell, which indicated that the values of the ω-3 related groups were significantly different from those of the control group. The control group maintained basal levels of autophagy. The ω-3 PUFA group showed a suppression of autophagy at late stages compared to the early stage suppression of the control group, while SIRT1 siRNA or autophagy inhibitor reversed ω-3 PUFA-mediated increases in autophagy. **c** Western blot showed a significant increased LC3 expression and decreased p62 levels in the ω-3 PUFA treatment group. However, the SIRT1 siRNA or autophagy inhibitor groups showed an increase in p62 levels but no increases in LC3 expression. Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01

To address the effects of ω-3 PUFA on oxidative stress, ROS production and expression of the antioxidative factors HO-1, NQO1, and UGT1A1 were measured. Data showed that the ROS levels increased approximately 3.1-fold in the TBI group compared with that in the sham group (*p* \< 0.05; Fig. [5](#Fig5){ref-type="fig"}a, b). ω-3 PUFA supplementation decreased ROS activity (*p* \< 0.05; Fig. [5](#Fig5){ref-type="fig"}a), while it significantly increased the levels of HO-1, NQO1, and UGT1A1 in lesioned cortices (*p* \< 0.05; Fig. [5](#Fig5){ref-type="fig"}b). 3-MA treatment reversed ω-3 PUFA-mediated inhibition of neuronal apoptosis and attenuated the neuroprotective effects associated with ω-3 PUFA treatment (*p* \< 0.05; Fig. [5](#Fig5){ref-type="fig"}c, d).Fig. 5ω-3 PUFA supplementation protects neurons via inhibition of oxidative stress in lesioned cortices. **a**, **b** ω-3 PUFA supplementation decreased ROS activity, while it significantly increased the levels the antioxidants HO-1, NQO1, and UGT1A1 in lesioned cortices. 3-MA attenuated ω-3 PUFA-induced activation of these antioxidant factors. **c**, **d** 3-MA reversed ω-3 PUFA-mediated inhibition of neuronal apoptosis and attenuated the neuroprotective effects associated with ω-3 PUFA treatment (*p* \< 0.05). Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01

ω-3 PUFA supplementation enhances autophagy via promoting nuclear export of Beclin-1 in lesioned cortices {#Sec22}
---------------------------------------------------------------------------------------------------------

Although Beclin-1 is expressed in both the nucleus and cytoplasm, it is generally acknowledged that the cytosolic localization of Beclin-1 is a prerequisite its prominent role in autophagy \[[@CR41], [@CR42]\]. Western blot and immunofluorescence staining analyses demonstrated that the expression of Beclin-1 in the cytosol, nuclei, and in total protein was increased 7 days after TBI and that ω-3 PUFA supplementation effectively increased Beclin-1 expression in the cytosol and in total protein of cells (*p* \< 0.05), but not in nuclear protein (*p* \> 0.05; Fig. [6](#Fig6){ref-type="fig"}a, b). In agreement with these findings, we found less cytoplasmic redistribution of nuclear Beclin-1 in the presence of the autophagy inhibitor, 3-MA, after TBI (Fig. [6](#Fig6){ref-type="fig"}a, b).Fig. 6ω-3 PUFA supplementation enhances autophagy via promoting nuclear export of Beclin-1 in lesioned cortices 7 days after TBI. **a**, **b** Immunofluorescence staining and western blot analyses demonstrated that expression levels of Beclin-1 in the cytosol, nuclei, and in total protein from lesioned cortices increased 7 days after TBI and that ω-3 PUFA supplementation effectively increased Beclin-1 expression in the cytosol and in total protein of cells from lesioned cortices (*p* \< 0.05), but not in nuclear protein (*p* \> 0.05). Moreover, less cytoplasmic redistribution of nuclear Beclin-1 was found in the presence of an autophagy inhibitor, 3-MA, after TBI. Representative photomicrographs of Beclin-1-positive neurons are shown (× 400). **c** Co-IP assays confirmed that ω-3 PUFA supplementation significantly increased interactions between cytoplasmic Beclin-1 and Bcl-2 after the TBI, while 3-MA treatment reversed these increases. Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01. Scale bars = 50 μm

Interaction between Beclin-1 and Bcl-2 can result in inhibition of apoptosis \[[@CR14]--[@CR16]\]. Given that the overall activity of cytoplasmic Bcl-2/Beclin-1 complexes is regulated by nuclear export of Beclin-1, we examined the interaction between cytoplasmic Beclin-1 and Bcl-2 to determine the anti-apoptotic effects of ω-3 PUFA supplementation after TBI. Results from the co-IP assay confirmed that ω-3 PUFA supplementation significantly increased interactions between cytoplasmic Beclin-1 and Bcl-2 after the TBI, while 3-MA treatment reversed these increases (Fig. [6](#Fig6){ref-type="fig"}c).

ω-3 PUFA supplementation elevates SIRT1 expression and deacetylase activity {#Sec23}
---------------------------------------------------------------------------

SIRTs are a family of deacetylases that require NAD+ as a cofactor for the deacetylation reaction \[[@CR38], [@CR43]\]. Consistent with our previous study, similar results were obtained by immunohistochemistry. SIRT1 immunoreactivity from lesioned cortices was significantly increased after ω-3 PUFA supplementation (*p* \< 0.05; Fig. [7](#Fig7){ref-type="fig"}a). SIRT1 protein levels were also upregulated after ω-3 PUFA supplementation 7 days after TBI (*p* \< 0.05; Fig. [7](#Fig7){ref-type="fig"}b). As SIRT1 is a NAD+-dependent histone deacetylase that affects NAD+ metabolism \[[@CR44], [@CR45]\], we also measured the NAD+/NADH ratio to detect SIRT1 activity. Treatment with ω-3 PUFA significantly increased the NAD+/NADH ratio (*p* \< 0.05; Fig. [7](#Fig7){ref-type="fig"}c).Fig. 7ω-3 PUFA supplementation elevates SIRT1 expression and deacetylase activity in lesioned cortices 7 days after TBI. **a** SIRT1 immunoreactivity in both neurons and microglia from lesioned cortices was significantly increased by ω-3 PUFA supplementation (2.64 ± 0.47 vs 1.74 ± 0.33, *p* \< 0.05). **b** SIRT1 levels were also upregulated after ω-3 PUFA supplementation (*p* \< 0.05). **c** The NAD+/NADH ratio was measured to detect SIRT1 activity. Treatment with ω-3 PUFA significantly increased the NAD+/NADH ratio (*p* \< 0.05). Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01. Scale bars = 50 μm

ω-3 PUFA supplementation increases Beclin-1 deacetylationby elevating SIRT1 activity {#Sec24}
------------------------------------------------------------------------------------

Post-translational modifications such as acetylation are critical for Beclin-1 transcription and nuclear export. Deacetylation of Beclin-1 can lead to elevation of autophagic responses \[[@CR26]\]. We therefore next focused on the molecular mechanism of Beclin-1 deacetylation and its role in driving nucleus-to-cytoplasm redistribution of Beclin-1 and subsequent autophagosome biogenesis. IP analysis showed that Beclin-1 deacetylation was increased after ω-3 PUFA supplementation compared with the TBI group (*p* \< 0.05; Fig. [8](#Fig8){ref-type="fig"}a). Nuclear export of Beclin-1 and autophagy activation induced by ω-3 PUFA supplementation were reversed by pharmacological inhibition of SIRT1 (sirtinol) (Fig. [8](#Fig8){ref-type="fig"}b, c), suggesting that the enhancement of autophagy by ω-3 PUFA was dependent on SIRT1 activity.Fig. 8ω-3 PUFA supplementation increases Beclin-1 deacetylation by elevating SIRT1 activity 7 days after TBI. **a** IP analysis showed an elevation of Beclin-1 deacetylation following ω-3 PUFA supplementation compared with the TBI group (*p* \< 0.05). **b** The nuclear export of Beclin-1 induced by ω-3 PUFA supplementation was reversed by pharmacological inhibition of SIRT (*p* \< 0.05). **c** Autophagy activation induced by ω-3 PUFA supplementation was reversed by pharmacological inhibition of SIRT1 (*p* \< 0.05). Values are expressed as mean ± standard deviation (*n* = 6 per group). N.S., *p* \> 0.05, \**p* \< 0.05, \*\**p* \< 0.01

Discussion {#Sec25}
==========

Accumulating evidence has demonstrated the benefits of ω-3 PUFA or its constituents against TBI-induced neural damage and secondary pathological processes \[[@CR46]--[@CR48]\]. We previously reported that ω-3 PUFA supplementation attenuates the inflammatory response by modulating microglial polarization through SIRT1-mediated deacetylation of the HMGB1/NF-κB pathway, leading to neuroprotective effects following experimental TBI \[[@CR33]\]. Taken together with our previously reported findings, the current study also demonstrated that ω-3 PUFA supplementation reduced brain edema and improved neurological function in lesioned cortices by inhibiting neuronal apoptosis. As a dietary supplement, ω-3 PUFA may be a suitable therapeutic candidate against trauma-induced mechanical injury and secondary neuronal apoptosis and may also provide novel therapeutic approaches for TBI.

TBI-induced secondary injury is a complicated pathophysiological process that affects neurological function \[[@CR2]--[@CR4]\]. Damaged mitochondria release excess ROS after TBI, which lead to oxidative stress and mitochondrial dysfunction \[[@CR5]--[@CR7]\]. Oxidative stress is critical for neurodegeneration after TBI and is also related to neuronal apoptosis \[[@CR15]\]. In response, oxidative stress-induced autophagy selectively degrades oxidized substances and damaged organelles to reduce oxidative injury, maintain normal mitochondrial function, and balance the intracellular microenvironment \[[@CR10], [@CR12], [@CR13]\]. In our study, ROS production and the expression of antioxidative factors were significantly increased after TBI. ω-3 PUFA supplementation decreased ROS production and enhanced the expression of these antioxidative factors. Upregulation of autophagy has been found to reduce TBI-induced oxidative stress and apoptosis, suggesting a protective role of autophagy after TBI \[[@CR9]\]. In the current study, compared with the TBI group, Beclin-1-positive neurons were increased after ω-3 PUFA supplementation and the expression of other autophagic markers were also dramatically increased, suggesting that ω-3 PUFA supplementation improves autophagy in neurons after TBI. Furthermore, the inhibition of neuronal apoptosis induced by ω-3 PUFA supplementation was reversed by pharmacological inhibition of autophagy, suggesting that autophagy plays a critical role in ω-3 PUFA-mediated neuroprotection after TBI.

Nuclear proteins may be important components of the autophagic machinery acting as reserves for cytoplasm proteins, which are exported to the cytoplasm during the maturation of autophagosomes \[[@CR41], [@CR42]\]. In our study, ω-3 PUFA supplementation also facilitated Beclin-1 nuclear export. Supporting this possibility, we found less cytoplasmic redistribution of nuclear Beclin-1 in the presence of the autophagy inhibitor after TBI, suggesting that ω-3 PUFA supplementation can activate the autophagy pathway by promoting the nuclear export of Beclin-1. Beclin-1 interacts with several binding partners and exerted multiple-biological effects, including cell metabolism, apoptosis, and autophagy \[[@CR15], [@CR18]\]. Bcl-2 and Bax, important apoptotic regulators tested in this study, are also regulated by Beclin-1. Additionally, caspase-mediated cleavage of ATGs and Beclin-1 can switch autophagy to apoptosis \[[@CR15], [@CR16]\]. Given that the overall activity of cytoplasmic Bcl-2/Beclin-1 complexes is regulated by nuclear export of Beclin-1, we examined the interaction between cytoplasmic Beclin-1 and Bcl-2 to determine the anti-apoptotic effects of ω-3 PUFA supplementation after TBI. Results from the co-IP assay confirmed that ω-3 PUFA supplementation significantly increased interactions between cytoplasmic Beclin-1 and Bcl-2 after TBI. These results indicate that ω-3 PUFA supplementation exerts neuroprotective effects and enhances autophagy after TBI, possibly by enhancing the nuclear export of Beclin-1.

Post-translational modifications like lysine deacetylations by SIRT1 regulate autophagy-mediated neuronal survival, supporting the idea that neuronal apoptosis is attenuated by SIRT1-mediated deacetylation of the autophagy pathway \[[@CR25], [@CR26], [@CR49]\]. Deacetylation at Beclin-1 lysine residues by SIRT1 influences autophagosome maturation \[[@CR26]\]. Our previous study \[[@CR33]\] confirmed that SIRT1 activity was involved in inflammatory mechanisms after TBI. In addition, SIRT1 levels were upregulated after ω-3 PUFA supplementation, indicating that ω-3 PUFA inhibited neuronal apoptosis in a SIRT1 deacetylation-mediated-dependent manner \[[@CR33]\]. Our IP analysis further showed that Beclin-1 acetylation was decreased in acetyl-lysine immunoprecipitate fractions after ω-3 PUFA supplementation compared with the TBI group. The nuclear export of Beclin-1 and autophagy activation induced by ω-3 PUFA supplementation was reversed by pharmacological inhibition of SIRT1. In agreement with these findings, SIRT1 siRNA neurons showed a suppression of autophagy at early stages compared to the late stage suppression of ω-3 PUFA treatment in vitro. Overall, these results indicate that ω-3 PUFA supplementation attenuates neuronal apoptosis and exerts neuroprotective effects by enhancing autophagy after TBI and is likely dependent on elevated SIRT1 levels. Because TBI-induced secondary injury is a complicated pathophysiological process, future studies involving the interaction between the apoptosis, autophagy, and neuroinflammation should be investigated to elucidate the mechanisms involved in the neuroprotective effects of ω-3 PUFA against TBI-induced neuronal apoptosis.

Conclusion {#Sec26}
==========

In summary, ω-3 PUFA supplementation inhibited neuronal apoptosis and exerted neuroprotective effects through enhancing the autophagy pathway after TBI. Moreover, ω-3 PUFA increased Beclin-1 deacetylation and its nuclear export and induced direct interactions between cytoplasmic Beclin-1 and Bcl-2 by increasing SIRT1 activity following TBI; subsequently leading to inhibition of neuronal apoptosis. These results indicate that ω-3 PUFA supplementation attenuates TBI-induced neuronal apoptosis by inducing the autophagy pathway through the upregulation of SIRT1-mediated deacetylation of Beclin-1.
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